Andrea Arfe
Overview
Explore the profile of Andrea Arfe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
587
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cooper A, Arfe A, Ricciuti B, Gagne A, Sholl L, Di Federico A, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100759.
PMID: 39802817
Introduction: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UTs) are a recently defined group of aggressive cancers in which the effectiveness of standard treatments for lung cancer is unknown. Methods: We collected clinical,...
2.
Elsallab M, Ouvina M, Arfe A, Bourgeois F
Clin Pharmacol Ther
. 2024 Dec;
PMID: 39655466
While cell and gene therapies (CGTs) have emerged as promising modalities to treat conditions with limited therapeutic options, their unconventional development is fraught with uncertainty, rendering them high-risk assets for...
3.
Kerioui M, Iasonos A, Gonen M, Arfe A
Stat Methods Med Res
. 2024 Aug;
33(10):1718-1730.
PMID: 39158499
In cancer research, basket trials aim to assess the efficacy of a drug using baskets, wherein patients are organized into subgroups according to their tumor type. In this context, using...
4.
Liu S, Erazo T, Jee J, Arfe A, Gupta A, Pike L, et al.
Eur J Cancer
. 2024 Aug;
210:114257.
PMID: 39151324
Introduction: No definitive answers currently exist regarding optimal first-line therapy for HER2-mutant NSCLC. Access to rapid tissue sequencing is a major barrier to precision drug development in the first-line setting....
5.
Johannet P, Abdelfattah S, Wilde C, Patel S, Walch H, Rousseau B, et al.
J Clin Oncol
. 2024 Aug;
42(32):3847-3857.
PMID: 39121438
Purpose: The molecular drivers underlying mucinous tumor pathogenicity are poorly understood. mutations predict metastatic burden and treatment resistance in mucinous appendiceal adenocarcinoma. We investigated the pan-cancer clinicopathologic relevance of variants....
6.
Han L, Arfe A, Trippa L
Am Stat
. 2024 Apr;
78(1):76-87.
PMID: 38680760
The use of simulation-based sensitivity analyses is fundamental for evaluating and comparing candidate designs of future clinical trials. In this context, sensitivity analyses are especially useful to assess the dependence...
7.
Arfe A, Muliere P
J Stat Plan Inference
. 2023 Jul;
222:241-251.
PMID: 37457239
We introduce a novel procedure to perform Bayesian non-parametric inference with right-censored data, the . This approximates the posterior law of summaries of the survival distribution (e.g. the mean survival...
8.
Arfe A, Narang C, Dubois S, Reaman G, Bourgeois F
J Natl Cancer Inst
. 2023 May;
115(8):917-925.
PMID: 37171887
Background: Many new molecular entities enter clinical development to evaluate potential therapeutic benefits for oncology patients. We characterized adult and pediatric development of the set of new molecular entities that...
9.
Avalos-Pacheco A, Ventz S, Arfe A, Alexander B, Rahman R, Wen P, et al.
JCO Precis Oncol
. 2023 Feb;
7:e2200606.
PMID: 36848613
Purpose: Adaptive clinical trials use algorithms to predict, during the study, patient outcomes and final study results. These predictions trigger interim decisions, such as early discontinuation of the trial, and...
10.
Barnett E, Schultz N, Stopsack K, Lam E, Arfe A, Lee J, et al.
Eur Urol
. 2022 Sep;
83(2):112-120.
PMID: 36123219
Background: BRCA2 alterations predict for a response to poly-ADP-ribose polymerase inhibition in metastatic castration-resistant prostate cancer (mCRPC). However, detection is hindered by insufficient tumor tissue and low sensitivity of cell-free...